Incretin-based therapy for diabetic ulcers: from bench to bedside

References

• Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, et al. The global burden of diabetic foot disease. Lancet. 2005;366(9498):1719–1724.
   PubMed Web of Science ®Google Scholar
• Saboo A, Rathnayake A, Vangaveti VN, et al. Wound healing effects of dipeptidyl peptidase-4 inhibitors: an emerging concept in management of diabetic foot ulcer-A review. Diabetes Metab Syndr. 2016;10(2):113–119.
   PubMed Web of Science ®Google Scholar
• Gurtner GC, Werner S, Barrandon Y, et al. Wound repair and regeneration. Nature. 2008;453(7193):314–321.
   PubMed Web of Science ®Google Scholar
• Lin JT, Chen HM, Chiu CH, et al. AMP-activated protein kinase activators in diabetic ulcers: from animal studies to phase II drugs under investigation. Expert Opin Investing Drugs. 2014;23(9):1253–1265.
   PubMed Web of Science ®Google Scholar
• Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007;117(5):1219–1222.
   PubMed Web of Science ®Google Scholar
• Marathe PH, Gao HX, Close KL. American diabetes association standards of medical care in diabetes 2017. J Diabetes. 2017;9(4):320–324.
   PubMed Web of Science ®Google Scholar
• Munir KM, Lamos EM. Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose? Expert Opin Pharmacother. 2017;18(9):839–841.
   PubMed Web of Science ®Google Scholar
• Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283.
   PubMedGoogle Scholar
• Pradhan L, Nabzdyk C, Andersen ND, et al. Inflammation and neuropeptides: the connection in diabetic wound healing. Expert Rev Mol Med. 2009;11:e2.
   PubMed Web of Science ®Google Scholar
• Wetzler C, Kampfer H, Stallmeyer B, et al. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J Invest Dermatol. 2000;115(2):245–253.
   PubMed Web of Science ®Google Scholar
• Johnson KE, Wilgus TA. Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. Adv Wound Care (New Rochelle). 2014;3(10):647–661.
   PubMedGoogle Scholar
• Raja SK, Garcia MS, Isseroff RR. Wound re-epithelialization: modulating keratinocyte migration in wound healing. Front Biosci. 2007;12:2849–2868.
   PubMed Web of Science ®Google Scholar
• Xiao-Yun X, Zhao-Hui M, Ke C, et al. Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation. Med Sci Monit. 2011;17(2):BR35–41.
   PubMed Web of Science ®Google Scholar
• Dinges HP, Redl H. Wound healing models for studying the formation of granulation tissue. Wien Klin Wochenschr. 1987;99(14):497–502.
   PubMed Web of Science ®Google Scholar
• Parks WC. Matrix metalloproteinases in repair. Wound Repair Regen. 1999;7(6):423–432.
   PubMed Web of Science ®Google Scholar
• Huijberts MS, Schaper NC, Schalkwijk CG. Advanced glycation end products and diabetic foot disease. Diabetes Metab Res Rev. 2008;24(Suppl. 1):S19–24.
   PubMedGoogle Scholar
• Kang HM, Kang Y, Chun HJ, et al. Evaluation of the in vitro and in vivo angiogenic effects of exendin-4. Biochem Biophys Res Commun. 2013;434(1):150–154.
   PubMed Web of Science ®Google Scholar
• Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol (1985). 2000;88(4):1474–1480.
   PubMed Web of Science ®Google Scholar
• Marfella R, Sasso FC, Rizzo MR, et al. Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes. Exp Diabetes Res. 2012;2012:892706.
   PubMedGoogle Scholar
• Brown LF, Yeo KT, Berse B, et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med. 1992;176(5):1375–1379.
   PubMed Web of Science ®Google Scholar
• Costa PZ, Soares R. Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci. 2013;92(22):1037–1045.
   PubMed Web of Science ®Google Scholar
• Du XL, Edelstein D, Dimmeler S, et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest. 2001;108(9):1341–1348.
   PubMed Web of Science ®Google Scholar
• Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev. 1995;16(3):390–410.
   PubMed Web of Science ®Google Scholar
• Orskov C, Rabenhoj L, Wettergren A, et al. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43(4):535–539.
   PubMed Web of Science ®Google Scholar
• Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev. 1998;161:55–70.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165.
   PubMed Web of Science ®Google Scholar
• Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res. 2004;36(11–12):852–858.
   PubMed Web of Science ®Google Scholar
• Hattori Y, Jojima T, Tomizawa A, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia. 2010;53(10):2256–2263.
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Matsui T, Takeuchi M, et al. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun. 2010;391(3):1405–1408.
   PubMed Web of Science ®Google Scholar
• Erdogdu O, Nathanson D, Sjoholm A, et al. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA-and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol. 2010;325(1–2):26–35.
   PubMed Web of Science ®Google Scholar
• Aronis KN, Chamberland JP, Mantzoros CS. GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. Metabolism. 2013;62(9):1279–1286.
   PubMed Web of Science ®Google Scholar
• Thompson MA, Ohnuma K, Abe M, et al. CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. Mini Rev Med Chem. 2007;7(3):253–273.
   PubMed Web of Science ®Google Scholar
• Zhong J, Maiseyeu A, Davis SN, et al. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res. 2015;116(8):1491–1504.
   PubMed Web of Science ®Google Scholar
• Doupis J, Veves A. DPP4 inhibitors: a new approach in diabetes treatment. Adv Ther. 2008;25(7):627–643.
   PubMed Web of Science ®Google Scholar
• Michel MC, Fliers E, Van Noorden CJ. Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism? Naunyn Schmiedebergs Arch Pharmacol. 2008;377(3):205–207.
   PubMed Web of Science ®Google Scholar
• Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol. 2009;157(8):1340–1351.
   PubMed Web of Science ®Google Scholar
• Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol. 2003;82(2):53–73.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol. 2011;55(1–3):10–16.
   PubMed Web of Science ®Google Scholar
• Ohnuma K, Yamochi T, Uchiyama M, et al. CD26 mediates dissociation of tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells. Mol Cell Biol. 2005;25(17):7743–7757.
   PubMed Web of Science ®Google Scholar
• Malhotra R, Singh L, Eng J, et al. Exendin-4, a new peptide from heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini. Regul Pept. 1992;41(2):149–156.
   PubMed Web of Science ®Google Scholar
• Harkavyi A, Whitton PS. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol. 2010;159(3):495–501.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.
   PubMed Web of Science ®Google Scholar
• Spinar J, Smahelova A. SAVOR TIMI 53-saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. Vnitr Lek. 2013;59(11):1003–1007.
   PubMedGoogle Scholar
• Wukich DK, Armstrong DG, Attinger CE, et al. Inpatient management of diabetic foot disorders: a clinical guide. Diabetes Care. 2013;36(9):2862–2871.
   PubMed Web of Science ®Google Scholar
• Wang Y, Parlevliet ET, Geerling JJ, et al. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br J Pharmacol. 2014;171(3):723–734.
   PubMed Web of Science ®Google Scholar
• Buldak L, Labuzek K, Buldak RJ, et al. Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(9):905–919.
   PubMed Web of Science ®Google Scholar
• Bacci S, Laurino A, Manni ME, et al. The pro-healing effect of exendin-4 on wounds produced by abrasion in normoglycemic mice. Eur J Pharmacol. 2015;764:346–352.
   PubMed Web of Science ®Google Scholar
• Roan JN, Cheng HN, Young CC, et al. Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing. J Surg Res. 2017;208:93–103.
   PubMed Web of Science ®Google Scholar
• Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Invest Dermatol Symp Proc. 2000;5(1):40–46.
   PubMed Web of Science ®Google Scholar
• Seo E, Lim JS, Jun JB, et al. Exendin-4 in combination with adipose-derived stem cells promotes angiogenesis and improves diabetic wound healing. J Transl Med. 2017;15(1):35.
   PubMed Web of Science ®Google Scholar
• Frank S, Madlener M, Werner S. Transforming growth factors beta1, beta2, and beta3 and their receptors are differentially regulated during normal and impaired wound healing. J Biol Chem. 1996;271(17):10188–10193.
   PubMed Web of Science ®Google Scholar
• Mentzel S, Dijkman HB, Van Son JP, et al. Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. J Histochem Cytochem. 1996;44(5):445–461.
   PubMed Web of Science ®Google Scholar
• Schurmann C, Linke A, Engelmann-Pilger K, et al. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. J Pharmacol Exp Ther. 2012;342(1):71–80.
   PubMed Web of Science ®Google Scholar
• Baticic Pucar L, Pernjak Pugel E, Detel D, et al. Involvement of DPP IV/CD26 in cutaneous wound healing process in mice. Wound Repair Regen. 2017;25(1):25–40.
   PubMed Web of Science ®Google Scholar
• Long M, Cai L, Li W, et al. DPP-4 inhibitors improve diabetic wound healing via direct and indirect promotion of epithelial-mesenchymal transition and reduction of scarring. Diabetes. 2018;67(3):518–531.
   PubMed Web of Science ®Google Scholar
• Zaruba MM, Theiss HD, Vallaster M, et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell. 2009;4(4):313–323.
   PubMed Web of Science ®Google Scholar
• Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10(8):858–864.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care. 2010;33(7):1607–1609.
   PubMed Web of Science ®Google Scholar
• King A, Balaji S, Keswani SG, et al. The role of stem cells in wound angiogenesis. Adv Wound Care (New Rochelle). 2014;3(10):614–625.
   PubMedGoogle Scholar
• Marchetti C, Di Carlo A, Facchiano F, et al. High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. Diabetologia. 2012;55(1):236–244.
   PubMed Web of Science ®Google Scholar
• Straino S, Di Carlo A, Mangoni A, et al. High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J Invest Dermatol. 2008;128(6):1545–1553.
   PubMed Web of Science ®Google Scholar
• Sinagra T, Merlo S, Spampinato SF, et al. High mobility group box 1 contributes to wound healing induced by inhibition of dipeptidylpeptidase 4 in cultured keratinocytes. Front Pharmacol. 2015;6:126.
   PubMed Web of Science ®Google Scholar
• Schaper NC, Havekes B. Diabetes: impaired damage control. Diabetologia. 2012;55(1):18–20.
   PubMed Web of Science ®Google Scholar
• Kavitha KV, Tiwari S, Purandare VB, et al. Choice of wound care in diabetic foot ulcer: a practical approach. World J Diabetes. 2014;5(4):546–556.
   PubMedGoogle Scholar